Recruiting PHASE4 INTERVENTIONAL 2-arm NCT05093374

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.

Sponsor: Medical University of Vienna

Conditions Exudative Macular Degeneration

Interventions anti-VEGF agent

Updated 5 times since 2021 Last updated: Nov 21, 2024 Started: Mar 1, 2021 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Exudative Macular Degeneration, this trial is actively recruiting participants. The trial is conducted by Medical University of Vienna and has accumulated 5 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE4
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Feb 2023 — Jul 2024 [monthly]

Recruiting PHASE4
Nov 2021 — Feb 2023 [monthly]

Recruiting PHASE4

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria